Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome) (IMDS001)
A Phase 2, Single Arm Study to Determine the Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk Myelodysplastic Syndrome
Study Objectives The aim of the study is to evaluate the safety and efficacy of the combination of 5-Aza-Cytidine + Thalidomide on the course of hrMDS patients.
Primary end point:
• To evaluate the overall response rate (CR+PR) of the combination of 5-Aza-Cytidine + Thalidomide in hrMDS patients (INT-2 and High risk as defined by IPSS).
Secondary end points:
- To evaluate the safety of the combination of Thalidomide+5-Aza-Cytidine in high risk MDS patients.
- Hematological improvement rate.
- Cytogenetic response.
- Progression free survival (PFS).
- Quality of life assessment (FACT: MDS and peripheral neuropathy QOL Questionnaires).
Study design:
This is a multicenter, phase II, single arm study designed to evaluate the safety and efficacy of the combination of Thalidomide+5-Aza-Cytidine in high risk MDS patients (INT-2 and High risk defined by IPSS) who are older than 18 years of age. Potential study subjects will sign an informed consent prior to undergoing any study related procedure. Number of patients to be enrolled 50.
Treatment plan: 5-aza-cytidine (75 mg m2/d) will be injected subcutaneously in 5-day cycle every 28 days, for a total of 12 cycles.
Thalidomide will be given at the dose of 50 mg/d, from day 1 until for 6 months together with 5-aza-cytidine .
Treatment period includes 5-aza-cytidine (75 mg m2/d) will be injected subcutaneously in 5-day cycle every 28 days. Total number of 12 cycles or until progression or toxicity. Cycle delay of maximum 2 weeks in case of hematological toxicity grade 3-4 at investigator discretion.
Duration of the follow up period is 6 months. Duration of study The duration of the treatment period is approximately 12 months. This time is required to complete the treatment, and to determine the safety profile and the response rate. The duration of the Follow period will be approximately a half year. The occurrence of PD will determine the duration of progression-free survival of each patient.
調査の概要
研究の種類
入学 (予想される)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
-
Tel-Aviv、イスラエル
- Hematolpgical department Tel Aviv Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patient is, in the investigator(s) opinion, willing and able to comply with the protocol requirements.
- Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
- Patient is older than 18 years at the time of signing the informed consent.
- Female patient is either post-menopausal or surgically sterilized or willing to use an acceptable double method of birth control (i.e., a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
- Female of childbearing potential must have a negative serum β-human chorionic gonadotropin ( beta sub unit-HCG) pregnancy test both 24 hours prior to beginning of therapy and then at 4 weeks intervals in women with regular menstrual cycles or every 2 weeks in women with irregular menstrual cycles during study treatment for subjects of childbearing potential.
- Male patient agrees to use an acceptable method for contraception (i.e., condom or abstinence) during study drug therapy (including dose interruption) and for 4 weeks after discontinuation of thalidomide therapy.
- Patient was diagnosed with myelodysplastic syndrome INT-2 or High risk according IPSS score .Bone marrow aspiration examination including cytogenetics performed up to 12 months before patient signing informed consent.
- Patient has a Performance Status 0-2 (WHO).
- Patient has a life-expectancy > 6 months
- Patient has not known active infectious hepatitis type B or C, or HIV infection.
- Patient is epopoietin resistant. Erythropoietin should be discontinued 28 days before starting treatment period.
Patient has the following laboratory values within 14 days before Baseline (day 1 of the Cycle 1):
- Platelet count ≥ 25 x 109/L without transfusion support within 7 days before the test.
- Absolute neutrophil count (ANC) ≥ 0.5 x 109/L without the use of growth factors.
- Aspartate transaminase (AST): ≤ 2.5 x the upper limit of normal (ULN).
- Alanine transaminase (ALT): ≤ 2.5 x the ULN.
- Total bilirubin: ≤ 1.5 x the ULN.
- Serum creatinine< 2 X the ULN.
Exclusion Criteria:
-
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
overall response rate measured by complete blood counts and bone marrow examinations
時間枠:at study entry. after 6 months and after one year
|
at study entry. after 6 months and after one year
|
overall response rate
時間枠:6 and 12 months
|
6 and 12 months
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
*safety *hematological improvement *cytogenetic response *progression free survival * Quality of life assessment (FACT: MDS and peripheral neuropathy QOL Questionnaires).
時間枠:at entry , 6 and 12 months
|
at entry , 6 and 12 months
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- 1. Greenberg PL. Risk factors and their relationship to prognosis in myelodysplastic syndromes. Leuk Res. 1998;22 Suppl 1:S3-6. 2. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica. 1998;83:358-368. 3. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998;92:68-75. 4. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-2440. 5. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895-3903. 6.
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
骨髄異形成症候群の臨床試験
-
Sanford HealthNational Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research Foundation; Cornelia... と他の協力者募集ミトコンドリア病 | 網膜色素変性症 | 重症筋無力症 | 好酸球性胃腸炎 | 多系統萎縮症 | 平滑筋肉腫 | 白質ジストロフィー | 痔瘻 | 脊髄小脳失調症3型 | フリードライヒ失調症 | ケネディ病 | ライム病 | 血球貪食性リンパ組織球症 | 脊髄小脳失調症1型 | 脊髄小脳性運動失調2型 | 脊髄小脳失調症6型 | ウィリアムズ症候群 | ヒルシュスプルング病 | 糖原病 | 川崎病 | 短腸症候群 | 低ホスファターゼ症 | レーバー先天性黒内障 | 口臭 | アカラシア心臓 | 多発性内分泌腫瘍 | リー症候群 | アジソン病 | 多発性内分泌腫瘍2型 | 強皮症 | 多発性内分泌腫瘍1型 | 多発性内分泌腫瘍2A型 | 多発性内分泌腫瘍2B型 | 非定型溶血性尿毒症症候群 | 胆道閉鎖症 | 痙性運動失調 | WAGR症候群 | アニリディア | 一過性全健忘症 | 馬尾症候群 | レフサム... およびその他の条件アメリカ, オーストラリア
5-aza-cytidine and Thalidomideの臨床試験
-
The University of Texas Health Science Center,...募集
-
Shirley Ryan AbilityLabRady Children's Hospital, San Diegoまだ募集していません脳性麻痺 | 拘縮
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)積極的、募集していない
-
M.D. Anderson Cancer CenterCelgene Corporation完了
-
University of LeipzigAbbVie; University Hospital Leipzig, Hematology Diagnostics Laboratory; University of Leipzig,...募集
-
M.D. Anderson Cancer Center終了しました
-
Children's Hospital of MichiganMerck Sharp & Dohme LLC; Boston Children's Hospital; William Beaumont Hospitals完了
-
M.D. Anderson Cancer CenterCelgene Corporation終了しました
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI)完了
-
M.D. Anderson Cancer CenterBayer完了